These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 698929)

  • 1. Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate.
    Ablin RJ; Bhatti RA; Guinan PD
    Cancer Res; 1978 Nov; 38(11 Pt 1):3702-6. PubMed ID: 698929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further evaluation of the effect of estrogen on tumor-associated immunity in prostatic cancer.
    Ablin RJ; Bhatti RA; Guinan PD
    Isr J Med Sci; 1979 Jan; 15(1):9-11. PubMed ID: 422345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulatory effects of oestrogen on immunological responsiveness. II. Suppression of tumour-associated immunity in patients with prostatic cancer.
    Ablin RJ; Bhatti RA; Guinan PD; Khin W
    Clin Exp Immunol; 1979 Oct; 38(1):83-91. PubMed ID: 93529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arming of normal leukocytes with sera from patients with adenocarcinoma of the prostate.
    Bhatti RA; Ablin RJ; Condoulis W; Guinan PD
    Cancer Res; 1979 Sep; 39(9):3328-31. PubMed ID: 476662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible suppression of host resistance by estrogen therapy for prostatic cancer.
    Ablin RJ
    Can Med Assoc J; 1976 Dec; 115(11):1082-4. PubMed ID: 1000436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal therapy and alterations of immunity in prostatic cancer.
    Ablin RJ
    Neoplasma; 1981; 28(3):345-50. PubMed ID: 7290262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated immunity in prostatic cancer as evaluated by tube antigen-induced leukocyte adherence inhibition: reactivity and specificity of responsiveness, and relationship to stage, grade and therapy.
    Bhatti RA; Ablin RJ; Guinan PD
    J Reticuloendothel Soc; 1979 Apr; 25(4):389-95. PubMed ID: 458777
    [No Abstract]   [Full Text] [Related]  

  • 8. Modulatory effects of estrogen on immunologic responsiveness. III. Effect of hormonal versus nonhormonal therapy on tumor-associated immunity in prostatic cancer.
    Ablin RJ
    Am J Reprod Immunol (1980); 1981 Aug; 1(4):206-9. PubMed ID: 7337156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory effects of oestrogen in prostatic cancer: update and further consideration.
    Ablin RJ
    Allergol Immunopathol (Madr); 1981; 9(1):63-70. PubMed ID: 7258047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-mediated antitumor immunity in breast cancer patients evaluated by antigen-induced leukocyte adherence inhibition in test tubes.
    Grosser N; Thomson DM
    Cancer Res; 1975 Sep; 35(9):2571-9. PubMed ID: 1097110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of human seminal plasma on tumour-associated immunity in patients with adenocarcinoma of the prostate.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    J Reprod Immunol; 1980 Feb; 1(5-6):337-45. PubMed ID: 7411523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evidence for increased cellular immunity to lung cancer antigen during Levamisole immunotherapy.
    Urist MM; Boddie AW; Townsend CM; Holmes EC
    J Thorac Cardiovasc Surg; 1977 Feb; 73(2):189-94. PubMed ID: 834057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of leukocyte adherence by 3-M potassium chloride extracts of human colorectal tumors.
    Ichiki AT; Quirin YP; Collmann IR; Sonoda T; Krauss S
    J Natl Cancer Inst; 1980 Mar; 64(3):419-23. PubMed ID: 6986496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-mediated immunity in prostatic cancer.
    Ablin RJ; Bhatti RA; Nagubadi S; Zamora S; Guinan PD
    Clin Oncol; 1980 Sep; 6(3):253-64. PubMed ID: 7428203
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. III. Inhibition of leucocyte migration.
    Ablin RJ; Marrow C; Guinan PD; Bruns GR; Sadoughi N; John T; Bush IM
    Urol Int; 1976; 31(6):444-58. PubMed ID: 1006873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of tumor-associated immunity by human seminal plasma and its possible role in the natural history of prostatic cancer.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    Eur Urol; 1980; 6(4):225-8. PubMed ID: 7389776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenocarcinoma R-3327 of the Copenhagen rat as a suitable model for immunological studies of prostate cancer.
    Lopez DM; Voigt W
    Cancer Res; 1977 Jul; 37(7 Pt 1):2057-61. PubMed ID: 301055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of diethylstilboesterol diphosphate on tumour-assoiciated immunity in prostatic cancer. A preliminary report.
    Bhatti RA; Ablin RJ; Guinan PD; Totonchi E; Zamora S
    Experientia; 1978 Oct; 34(10):1364-5. PubMed ID: 738427
    [No Abstract]   [Full Text] [Related]  

  • 20. Cell-mediated immunity and serum blocking factors in cancer patients during chemotherapy and immunotherapy.
    Noonan FP; Halliday WJ; Wall DR; Clunie GJ
    Cancer Res; 1977 Aug; 37(8 Pt 1):2473-80. PubMed ID: 872076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.